- World Pharma News Home » Financial » GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
(a free service delivered by FeedBurner)
GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
GlaxoSmithKline [LSE/NYSE: GSK] and Genelabs Technologies, Inc. [NASDAQ: GNLB] have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK’s effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
Discuss Add this link to... Bury
Comments